Profound Medical Corp. remains rated Sell due to persistent competitive pressures, missed growth promises, and deteriorating financials. PROF's recent 20% stock spike followed news of a Dallas Medical ...
Profound Medical Corp's TULSA-PRO system has the potential to disrupt the surgical treatment of prostate disease. The company is delivering solid growth in recurring and capital revenues. Despite high ...
Profound Medical (NASDAQ:PROF) just reported results for the fourth quarter of 2023. Profound Medical reported earnings per share of -42 cents. This was below the analyst estimate for EPS of -32 cents ...
Profound Medical (NASDAQ:PROF) just reported results for the second quarter of 2024. Profound Medical reported earnings per share of -28 cents. This was above the analyst estimate for EPS of -29 cents ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results